Kate advises clients on all issues relating to the enforcement and validity of patents and supplementary protection certificates, as well as IP licensing disputes. Her previous cases have involved antibody technology, small molecules, medical devices and dosage regimens. Kate has experience of litigating in the UK High Court and Court of Appeal, as well as coordinating cross-border disputes in Europe, Asia and North America.

Some of Kate’s work highlights include:

• Teva and Samsung Bioepis v Novartis – UK patent litigation relating to ranibizumab pre-filled syringes, and multi-jurisdictional coordination.
• Lilly v Novartis; UCB v Novartis – European patent revocation and infringement proceedings relating to IL-17AF antibody patents, and multi-jurisdictional coordination.
• Teva v Eli Lilly – UK patent litigation relating to anti-CGRP antibodies.
• Teva v Janssen – UK patent litigation relating to paliperidone palmitate dosage regimens.
• Otsuka v GW Pharma – IP licence dispute relating to cannabidiol treatment for epilepsy.
• Coordinating multinational patent litigation strategies for blockbuster pharmaceutical products in Europe, Asia and North America.

Shortly after qualifying into the patent litigation department, Kate went on a five month secondment to an international innovator pharmaceutical company, focusing primarily on biologics. Prior to this, whilst training at Bristows, she spent three months in the international litigation team at a leading internet services/technology company and was also seconded to the patents department of a generic pharmaceutical company.